Statins Reduce Hepatocellular Carcinoma Risk in Patients with Chronic Kidney Disease and End-Stage Renal Disease: A 17-Year Longitudinal Study
Open Access
Abstract
Hepatocellular carcinoma (HCC) is the most common cancer in end-stage renal disease (ESRD) patients in Taiwan. Whether statin therapy associated with the HCC risk in hyperlipidemic patients with chronic kidney disease (CKD) and ESRD is unclear. Using population-based insurance claim data from Taiwan, we identified from hyperlipidemic patients taking statins or not (677,364 versus 867,707) in 1999–2015. Among them, three pairs of propensity score matched statin and non-statin cohorts were established by renal function: 413,867 pairs with normal renal function (NRF), 46,851 pairs with CKD and 6372 pairs with ESRD. Incidence rates of HCC were compared, by the end of 2016, between statin and non-statin cohorts, between hydrophilic statins (HS) and lipophilic statins (LS) users, and between statin-ezetimibe combination therapy (SECT) and statin monotherapy (SM) users. The HCC incidence increased progressively from NRF to CKD and ESRD groups, was lower in the statin cohort than in the non-statin cohort, with the differences of incidence per 10,000 person-years increased from (7.77 vs. 21.4) in NRF group to (15.8 vs. 37.1) in CKD group to (19.1 vs. 47.8) in ESRD group. The incidence increased with age, but the Cox method estimated hazard ratios showed a greater statin effectiveness in older patients. Among statin users, the HCC incidence was lower in HS users than in LS users, and lower in SECT users than in SM users, but the difference was significant only in the NRF group. Hyperlipidemic patients with CKD and ESRD receiving statins are at reduced HCC risks; the treatment effectiveness is superior for HS users than for LS users, and for SECT users than for SM users, but not significant.Keywords
Funding Information
- Taiwan Ministry of Health and Welfare Clinical Trial Center (MOHW109-TDU-B-212-114004)
- MOST Clinical Trial Consortium for Stroke (MOST 109-2321-B-039-002)
- China Medical University Hospital (DMR-108-154)
- Tseng-Lien Lin Foundation of Taichung, Taiwan (NA)
- Ditmanson Medical Foundation Chiayi Christian Hospital (R-109-17)
This publication has 36 references indexed in Scilit:
- Safety and efficacy of ezetimibe: A meta-analysisInternational Journal of Cardiology, 2015
- Association of nonalcoholic fatty liver disease (NAFLD) with hepatocellular carcinoma (HCC) in the United States from 2004 to 2009Hepatology, 2015
- Clinical Efficacy and Safety of Ezetimibe on Major Cardiovascular Endpoints: Systematic Review and Meta-Analysis of Randomized Controlled TrialsPLOS ONE, 2015
- Rosuvastatin pharmacokinetics and pharmacogenetics in Caucasian and Asian subjects residing in the United StatesEuropean Journal of Clinical Pharmacology, 2015
- HMG CoA reductase inhibitors (statins) for people with chronic kidney disease not requiring dialysisCochrane Database of Systematic Reviews, 2014
- Exposure to statins and risk of common cancers: a series of nested case-control studiesBMC Cancer, 2011
- Increased risk of cancer in chronic dialysis patients: a population-based cohort study in TaiwanNephrology Dialysis Transplantation, 2011
- Hepatitis C progressing to hepatocellular carcinoma: the HCV dialysis patient in dilemmaJournal of Viral Hepatitis, 2009
- Characteristics of hepatocellular carcinoma in hemodialysis patients in hepatitis B endemic area.2003
- Cancer in patients on dialysis for end-stage renal disease: an international collaborative studyThe Lancet, 1999